Last reviewed · How we verify
Albendazole plus Praziquantel
Albendazole and praziquantel are antihelmintic agents that disrupt microtubule formation and parasite motility, causing paralysis and death of various parasitic worms.
Albendazole and praziquantel are antihelmintic agents that disrupt microtubule formation and parasite motility, causing paralysis and death of various parasitic worms. Used for Soil-transmitted helminthiasis (hookworm, roundworm, whipworm), Schistosomiasis, Taeniasis (tapeworm infection).
At a glance
| Generic name | Albendazole plus Praziquantel |
|---|---|
| Sponsor | Navrongo Health Research Centre, Ghana |
| Drug class | Antihelmintic combination |
| Target | β-tubulin (albendazole); calcium channels (praziquantel) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | FDA-approved |
Mechanism of action
Albendazole inhibits β-tubulin polymerization in parasitic nematodes and cestodes, preventing microtubule assembly and causing energy depletion. Praziquantel increases cell membrane permeability to calcium in trematodes and cestodes, leading to paralysis and detachment from host tissues. The combination provides broad-spectrum coverage against multiple helminth species.
Approved indications
- Soil-transmitted helminthiasis (hookworm, roundworm, whipworm)
- Schistosomiasis
- Taeniasis (tapeworm infection)
- Polyparasitic infections in endemic regions
Common side effects
- Abdominal pain
- Nausea
- Diarrhea
- Dizziness
- Headache
Key clinical trials
- Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel (PHASE4)
- HIV And Parasitic Infection (HAPI) Study (NA)
- Oxfendazole in Mild Parenchymal Brain Cysticercosis (PHASE2, PHASE3)
- Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis (PHASE4)
- Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control (NA)
- Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) (PHASE3)
- Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children (NA)
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albendazole plus Praziquantel CI brief — competitive landscape report
- Albendazole plus Praziquantel updates RSS · CI watch RSS
- Navrongo Health Research Centre, Ghana portfolio CI